Want to see EDSA full AI Analyst Report?
EDSA Stock Chart & Stats
$5.25
-$0.03(-0.57%)
At close: 4:00 PM EDT
$5.25
-$0.03(-0.57%)
Day’s Range― - ―
52-Week Range$0.72 - $20.32
Previous CloseN/A
Volume52.26K
Average Volume (3M)95.23K
Market Cap
$50.57M
Enterprise Value$43.04
Total Cash (Recent Filing)$10.00M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta-0.43
Next Earnings
Aug 07, 2026EPS Estimate
-0.44Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.34
Shares Outstanding9,633,223
10 Day Avg. Volume58,770
30 Day Avg. Volume95,231
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)1.13
Price to Sales (P/S)0.00
P/FCF Ratio-1.91
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$21.00Price Target Upside300.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-1.87
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative Balance Sheet With Negligible DebtNet-debt neutrality and roughly $12.4M of equity reduce near-term solvency risk for a development-stage biotech. This structural liquidity buffer lengthens the runway versus similarly loss-making peers and lowers refinancing urgency while pipeline programs advance.
Committed Near-term Financing Via Insider-led PIPEAn insider-led PIPE that brings ~$3.5M strengthens the company's ability to fund clinical work without immediate commercial revenue. Insider participation signals alignment and continued support, improving the visibility of funding for upcoming trial milestones and program advancement.
Positive Exploratory Clinical Signals For Lead AssetExploratory Phase 2/3 signals that paridiprubart may reduce mortality and improve kidney outcomes support the scientific rationale and de-risk target biology. If confirmed, such durable efficacy across organs could expand indications and partner interest, underpinning long-term value creation.
Bears Say
Minimal Recurring Revenue And Large Net LossesWith almost no product revenue and roughly $10.4M in trailing losses, Edesa remains fully dependent on financing rather than operating cash flow. Persistent negative earnings structurally increase funding needs and constrain reinvestment until clinical success or partner deals materialize.
Sustained Negative Cash GenerationOperating cash burn near $7.6M TTM means the business consumes capital while pre-revenue. This structural cash outflow pattern forces repeated financing rounds or partnerships, creating execution risk if capital markets tighten or if clinical timelines slip.
Dependence On Equity Issuance And Increased Dilution CapacityExpanding the equity incentive pool and shifting CEO pay to predominantly RSUs institutionalizes reliance on equity compensation and issuance to conserve cash. Structurally, this raises dilution risk for existing holders and signals ongoing capital substitution rather than near-term operational revenue generation.
Edesa Biotech News
EDSA FAQ
What was Edesa Biotech’s price range in the past 12 months?
Edesa Biotech lowest stock price was $0.72 and its highest was $20.32 in the past 12 months.
What is Edesa Biotech’s market cap?
Edesa Biotech’s market cap is $50.57M.
When is Edesa Biotech’s upcoming earnings report date?
Edesa Biotech’s upcoming earnings report date is Aug 07, 2026 which is in 9 days.
How were Edesa Biotech’s earnings last quarter?
Edesa Biotech released its earnings results on May 14, 2026. The company reported -$0.49 earnings per share for the quarter, missing the consensus estimate of -$0.26 by -$0.23.
Is Edesa Biotech overvalued?
According to Wall Street analysts Edesa Biotech’s price is currently Undervalued.
Does Edesa Biotech pay dividends?
Edesa Biotech does not currently pay dividends.
What is Edesa Biotech’s EPS estimate?
Edesa Biotech’s EPS estimate is -0.44.
How many shares outstanding does Edesa Biotech have?
Edesa Biotech has 9,633,223 shares outstanding.
What happened to Edesa Biotech’s price movement after its last earnings report?
Edesa Biotech reported an EPS of -$0.49 in its last earnings report, missing expectations of -$0.26. Following the earnings report the stock price went down -10.678%.
Which hedge fund is a major shareholder of Edesa Biotech?
Currently, no hedge funds are holding shares in EDSA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Edesa Biotech Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$21.00 (300.00% Upside)
$21.00 (300.00% Upside)
Blogger Sentiment
Bullish
EDSA Sentiment 70%
Sector Average 65%
Sector Average 65%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 5.9%
Last 30 Days ▼ 4.4%
Last 30 Days ▼ 4.4%
Technicals
SMA
Positive
20 days / 200 days
Momentum
118.75%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-24.73%
Trailing 12-Months
Company Description
Edesa Biotech
Edesa Biotech, Inc. is a biopharmaceutical firm focused on discovering, developing, and commercializing clinical-stage treatments for inflammatory and immune system disorders where current medical options are inadequate. The company's key pipeline assets include EB05, a monoclonal antibody undergoing a Phase 3 clinical trial for acute respiratory distress syndrome (ARDS) in COVID-19 patients, and EB01, a topical therapy in a Phase 2B clinical study addressing chronic allergic contact dermatitis. Furthermore, Edesa has a licensing collaboration with NovImmune SA to advance monoclonal antibodies specifically designed to target TLR4 and CXCL10. This company was established in 2015 and is based in Markham, Canada.
EDSA Stock 12 Month Forecast
Average Price Target
$21.00
▲(300.00% Upside)
Technical Analysis
Eterna Therapeutics
―
Lipocine
―
XTL Biopharmaceuticals Sponsored ADR
―
Cocrystal Pharma
―
BioVie
―
Ownership Overview
21.56% Insiders
1.30% Mutual Funds
22.38% Other Institutional Investors
53.91% Public Companies and
Individual Investors